<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059462</url>
  </required_header>
  <id_info>
    <org_study_id>10630</org_study_id>
    <nct_id>NCT00059462</nct_id>
    <nct_alias>NCT00048191</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection</brief_title>
  <official_title>Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 Administration in Patients With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to Patients on HAART Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in&#xD;
      HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2 SA</intervention_name>
    <description>HAART and Bay 50-4798</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>HAART alone</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented HIV infection (positive enzyme linked immuno assay (EIA) confirmed by&#xD;
             Western Blot).&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Plasma HIV viral load less than 10,000 copies/ml (by bDNA assay or less than 14,000&#xD;
             copies/ml by RT-PCR) on at least 2 occasions within 8 weeks prior to study entry with&#xD;
             no more than a 0.5 log increase between the most recent and the earlier viral load&#xD;
             measurements.&#xD;
&#xD;
          -  CD4 + T-cell count greater than or equal to 200/mm(3) on at least 2 occasions within 8&#xD;
             weeks of study entry.&#xD;
&#xD;
          -  On a stable HAART regimen for greater than or equal to 8 weeks.&#xD;
&#xD;
          -  Karnofsky Score greater than or equal to 80.&#xD;
&#xD;
          -  Written informed consent. Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with IL-2 or an IL-2 analogue.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. - Use of any known immunomodulators, cytokines, growth&#xD;
             factors or systemic corticosteroids (e.g. prednisone greater than or equal to 15&#xD;
             mg/day or equivalent) within 4 weeks prior to study enrollment.&#xD;
&#xD;
          -  History of an AIDS defining illness by the Centers for Disease Control (CDC)&#xD;
             definition within 8 weeks prior to study entry.&#xD;
&#xD;
          -  Acute bacterial or viral infection within 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Received an immunization within 4 weeks prior to enrollment.&#xD;
&#xD;
          -  History of autoimmune disease including psoriasis, inflammatory bowel disease.&#xD;
&#xD;
          -  Medical history of transplantation (solid organ or bone marrow).&#xD;
&#xD;
          -  Received an investigational drug in the past 30 days other than Food and Drug&#xD;
             Administration (FDA) sanctioned treatment IND antiretroviral agents.&#xD;
&#xD;
          -  Renal insufficiency with a serum creatinine level greater than 1.5 times the upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  Bone marrow suppression as defined by one or more of the following: granulocyte count&#xD;
             less than 1,000 cells/ÂµL; hemoglobin less than 9.0g (females) or less than 9.5g&#xD;
             (males); or platelet count less than 75,000 cells/ÂµL.&#xD;
&#xD;
          -  Evidence of hepatic disease indicated by one or more of the following: SGOT (AST)&#xD;
             and/or SGPT (ALT) greater than 5 times the upper limit of normal. Bilirubin greater&#xD;
             than 2 times the upper limit of normal (except for patients with known Gilbert's&#xD;
             syndrome or those receiving indinavir who may be enrolled if the serum bilirubin is&#xD;
             less than or equal to 5 times the upper limit of normal).&#xD;
&#xD;
          -  Active cardiac disease (coronary artery disease, congestive heart failure or&#xD;
             cardiomyopathy) requiring treatment with any of the following medications:&#xD;
             antiarrhythmic agents including digitalis, anti-anginal drugs including topical or&#xD;
             systemic nitrates, calcium channel blockers, and beta blockers, and afterload reducers&#xD;
             including ACE inhibitors. Patients requiring any of these medications solely for the&#xD;
             treatment of hypertension remain eligible for the study.&#xD;
&#xD;
          -  Presence of significant cardiac insufficiency (greater than or equal to New York Heart&#xD;
             Association Grade 2).&#xD;
&#xD;
          -  Diagnosis of an active malignancy requiring treatment with systemic cytotoxic&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Active alcohol or substance abuse which, in the opinion of the investigator, will&#xD;
             seriously compromise the subject's ability to adhere with the demands of the study.&#xD;
&#xD;
          -  Any central nervous system (CNS) disease that requires active treatment with&#xD;
             anticonvulsants.&#xD;
&#xD;
          -  Use of an antimetabolite such as hydroxyurea within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Known co-infection with Hepatitis B or C virus unless serum transaminases are less&#xD;
             than or equal to 2 times the upper limit of normal on at least two occasions within 8&#xD;
             weeks prior to study entry.&#xD;
&#xD;
          -  Known CD4 Nadir less than 50 cells/mm(3).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-2602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 25, 2003</study_first_submitted>
  <study_first_submitted_qc>May 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2003</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

